Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
February 18 2021 - 7:00AM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company primarily focused on developing
proprietary therapeutics designed to extend life or improve the
quality of life for cancer patients, today announced the
appointment of Laura Kelly as Director of Clinical Operations. Ms.
Kelly will be responsible for managing Monopar’s clinical programs,
including the recently launched Phase 2b/3 VOICE trial for the
Company’s lead drug candidate Validive®.
Ms. Kelly brings a wealth of clinical research experience,
including oncology and the execution of Phase 1 through Phase 4
clinical trials, to the Monopar team. Prior to Monopar, Ms. Kelly
served in strategic and clinical operation leadership roles at
Merck/EMD Serono, AbbVie, Abbott Labs, and Amgen. “The addition of
Laura to the team comes at an ideal time, given the rapid ramp-up
in development efforts resulting from the positive progression of
our clinical programs,” said Chandler Robinson, MD, Chief Executive
Officer of Monopar. “She will be a valuable contributor not only to
our Validive clinical trial, but also to our camsirubicin clinical
program and MNPR-101 as it moves toward an IND.”
“We are very pleased to welcome Laura to the team,” said Andrew
Mazar, PhD, Chief Scientific Officer of Monopar. “Her extensive
experience in clinical operations combined with strong leadership
skills should allow her to make an immediate impact on the timely
enrollment and execution of our clinical trials.”
About Monopar Therapeutics Inc. Monopar
Therapeutics is a clinical-stage biopharmaceutical company
primarily focused on developing proprietary therapeutics designed
to extend life or improve the quality of life for cancer patients.
Monopar's pipeline consists of Validive for the prevention of
chemoradiotherapy-induced severe oral mucositis in oropharyngeal
cancer patients; camsirubicin for the treatment of advanced soft
tissue sarcoma; and a late-stage preclinical antibody, MNPR-101,
for advanced cancers and severe COVID-19. For more information,
visit: www.monopartx.com.
Forward-Looking Statements Statements
contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Examples of these forward-looking
statements include statements concerning: whether Ms. Kelly will be
a valuable contributor and make an immediate impact on the timely
enrollment and execution of Monopar’s Validive clinical trial,
camsirubicin clinical program and MNPR-101; and whether MNPR-101
will move toward an IND, if at all. The forward-looking statements
involve risks and uncertainties including, but not limited to not
successfully enrolling or completing the VOICE clinical trial, if
at all; the camsirubicin clinical partner not successfully
enrolling or completing its clinical trial, if at all; MNPR-101 not
becoming a viable clinical program; the requirement for additional
capital to complete future clinical development of Validive in 2022
and beyond; if successful, the potential for Validive
commercialization, including uncertainties about levels of demand;
and the significant and general risks and uncertainties surrounding
the research, development, regulatory approval and
commercialization of therapeutics. Actual results may differ
materially from those expressed or implied by such forward-looking
statements. Risks are described more fully in Monopar's filings
with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Monopar undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.
Any forward-looking statements contained in this press release
represent Monopar’s views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date.
CONTACT: Monopar Therapeutics
Inc: Investor Relations Kim R.
Tsuchimoto Chief Financial
Officer kimtsu@monopartx.com Follow Monopar on
social media for updates: Twitter @MonoparTx
Linkedin Monopar
Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Sep 2023 to Sep 2024